This week in charts
Global debt levels
Sources of return
2024 style box performance
Private equity
Yield curve impact on small & mid caps
Intra-year declines vs. calendar year returns
Stocks outperforming the S&P 500
Gold
Returns by asset class
Will weight-loss drugs lead to upheaval in the sugar market?
So-called glucagon-like peptide-1 receptor agonists (GLP-1s) contained in such drugs as Wegovy, Mounjaro and Ozempic curb users’ appetites and are being hailed as game changers for tackling obesity and potentially a range of other conditions, from diabetes to addiction. They could also lead to an upheaval in sugar markets.
Fears that Americans on GLP-1s will stop buying treats have already spooked businesses and investors. Mondelez and PepsiCo stocks took a hit after Walmart chief executive John Furner reported that customers on these drugs were buying fewer groceries. Hershey has also acknowledged experiencing a “mild impact” on sales, attributed to the growing use of GLP-1 medications.
Sugar traders, for now, are brushing off concerns about weight-loss drugs’ potential to dent demand. Perhaps they’re battle-hardened — decades of sugar-is-bad campaigns have not made a dent in global consumption, which has quadrupled in the past 60 years, according to Professor Paul Behrens of the British Academy. Sweet treats still fly off the shelves in most markets, and until recently sugar prices have been riding high on weather woes and rising production costs.
There are other reasons for traders’ nonchalance. So far, Ozempic and other drugs are pricey and only available to a small segment of wealthy consumers in developed countries. Even if these appetite-suppressing drugs do start reducing demand, the thinking goes, it’ll be a slow burn, giving markets and sugar producers plenty of time to adjust.
That “yet” looms large. In the UK, for example, the government plans to roll out Mounjaro on the NHS. Prices are likely to drop elsewhere too, especially as pharmaceutical companies race to sell compounded versions of drugs, circumventing patents.
If prices fall and access broadens, the ripple effects could reach middle-income and even developing markets. The obesity epidemic and slew of health conditions that come with it are not limited to rich western nations. In India, the world’s biggest sugar consumer, rates of diabetes and obesity are soaring. Indians consume a staggering 29mn tonnes of sugar annually — 15 per cent of global demand. Even a modest uptake of GLP-1s there could shake the market in ways that traders might find hard to ignore.
Tracking sugar consumption is notoriously tricky, though. There’s a real risk, therefore, that these trends could develop under the radar before the industry wakes up to what’s happening.
Sugar’s adaptability — it can be repurposed into ethanol for fuel or bioplastics — might provide a cushion, especially as demand for low-carbon fuels and renewable materials grows. Yet this transition won’t happen overnight.
The week’s fun finds
How do you fit everything in the universe on a chart?
This chart shows every object that has ever existed, and raises a question: is the universe a black hole?
